Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Francesca Bruce

Francesca Bruce has been writing news and analysis about all things affecting the pharmaceutical industry since 2008. She has paid special attention to policy and regulatory developments but particularly likes to write about market access and how medicines may  - or may not  -  make it to patients. She generally writes about Europe, but really enjoys uncovering news from further corners of the globe, especially Latin America and the Middle East.
Advertisement
Set Alert for Articles By Francesca Bruce

Latest From Francesca Bruce

Lost $700m Opportunity As PTC Bids Farewell to Translarna in CF

In withdrawing its European marketing application for Translarna in cystic fibrosis, PTC Therapeutics has bid farewell to a market opportunity once pegged at $700m.

Commercial Market Intelligence

Multi-Company Product Listing Agreements On The Rise In Canada

The pan-Canadian Pharmaceutical Alliance has negotiated product listing agreements with three hepatitis C drug makers in one of its first major negotiations with multiple manufacturers. The pCPA may want to negotiate more deals with several companies at once, particularly those with drugs in crowded markets.

Market Access Pricing Strategies

Politics Dilute Germany’s AMNOG Updates: Impact On Pharma Firms

New updates to Germany’s 2011 AMNOG healthcare reform act could lead to more conservative prescribing and benefit assessments for older products. Pricing measures were dropped but will likely resurface after September’s general elections.

Market Access Policy & Regulation

Brexit And International Reference Pricing To Cost Companies Billions Of Dollars

Companies could lose hundreds of millions of dollars thanks to the impact of Brexit on international reference pricing. Brexit has other market access implications too, for example on the ebb and flow of parallel trade.

Brexit Market Access

Germany Cancels Confidential Drug Pricing

Plans to make pharmaceutical prices in Germany confidential are likely to be shelved, but other measures could help companies better navigate price transparency.

Market Access Policy

How Broad Labels May Make Market Access In Germany More Difficult

Companies might have to rethink their German market access strategies if new legislation is passed to informs doctors of the outcome of AMNOG benefit assessments.

Market Access Policy
See All
Advertisement
UsernamePublicRestriction

Register